RT Journal Article SR Electronic T1 Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.30.20217364 DO 10.1101/2020.10.30.20217364 A1 Ashraf, Sohaib A1 Ashraf, Shoaib A1 Ashraf, Moneeb A1 Imran, Muhammad Ahmad A1 Kalsoom, Larab A1 Siddiqui, Uzma Nasim A1 Farooq, Iqra A1 Habib, Zaighum A1 Ashraf, Sidra A1 Ghufran, Muhammad A1 Akram, Muhammad Kiwan A1 Majeed, Nighat A1 Abdin, Zain-ul A1 Akmal, Rutaba A1 Rafique, Sundas A1 Nawaz, Khawar A1 K Yousaf, Muhammad Ismail A1 Arshad, Shahroze A1 Ahmad, Sohail A1 Shahab, Muhammad Sarmad A1 Nadeem, Muhammad Faisal A1 Azam, Muhammad A1 Zheng, Hui A1 Malik, Amber A1 Ayyaz, Mahmood A1 Mahmud, Talha A1 Saboor, Qazi Abdul A1 Ahmad, Ali A1 Ashraf, Muhammad A1 Izhar, Mateen YR 2020 UL http://medrxiv.org/content/early/2020/11/27/2020.10.30.20217364.abstract AB BACKGROUND No definitive treatment exists for Coronavirus Disease 2019 (COVID-19). Honey and Nigella sativa (HNS) have established antiviral properties. Hence, we investigated efficacy of HNS against COVID-19.METHODS We conducted a multicenter, placebo-controlled, randomized clinical trial at 4 centers in Pakistan. RT-PCR confirmed COVID-19 adults showing moderate or severe disease were enrolled in the study. Patients presenting with multi-organ failure, ventilator support, and chronic diseases (except diabetes mellitus and hypertension) were excluded. Patients were randomly assigned in 1:1 ratio to receive either honey (1 gm/Kg/day) and Nigella sativa seeds (80 mg/Kg/day) or placebo up-to 13 days along with standard care. The outcomes included symptom alleviation, viral clearance, and a 30-day mortality in intention-to-treat population. This trial was registered with ClinicalTrials.gov, NCT04347382.FINDINGS Three hundred and thirteen patients - 210 moderate and 103 severe - underwent randomization from April 30 to July 29, 2020. Among these, 107 were assigned to HNS whereas 103 to placebo for moderate cases. For severe cases, 50 were given HNS and 53 were given placebos. HNS resulted in ∼50% reduction in time taken to alleviate symptoms as compared to placebo (Moderate (4 versus 7 days), Hazard Ratio [HR]: 6.11; 95% Confidence Interval [CI]: 4.23-8.84, P<0.0001 and severe (6 versus 13 days) HR: 4.04; 95% CI, 2.46-6.64, P<0.0001). HNS also cleared the virus 4 days earlier than placebo group in moderate (6 versus 10 days, HR: 5.53; 95% CI: 3.76-8.14, P<0.0001) and severe cases (8.5 versus 12 days, HR: 4.32; 95% CI: 2.62-7.13, P<0.0001). HNS further led to a better clinical score on day 6 with normal activity resumption in 63.6% versus 10.9% among moderate cases (OR: 0.07; 95% CI: 0.03-0.13, P<0.0001) and hospital discharge in 50% versus 2.8% in severe cases (OR: 0.03; 95% CI: 0.01-0.09, P<0.0001). In severe cases, mortality rate was four-fold lower in HNS group than placebo (4% versus 18.87%, OR: 0.18; 95% CI: 0.02-0.92, P=0.029). No HNS-related adverse effects were observed.INTERPRETATION HNS significantly improved symptoms, viral clearance and mortality in COVID-19 patients. Thus, HNS represents an affordable over the counter therapy and can either be used alone or in combination with other treatments to achieve potentiating effects against COVID-19.FUNDING Funded by Smile Welfare Organization, Shaikh Zayed Medical Complex, and Services Institute of Medical Sciences.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04347382Funding StatementFunded by Smile Welfare Organization, Shaikh Zayed Medical Complex and Services Institute of Medical SciencesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan approval ID SZH/IRB/0026/2020 and IRB Services Institute of Medical Sciences, Lahore, Pakistan approval ID IRB/2020/658/SIMSAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesClinical data is available as additional file and raw data can be provided on request to corresponding author